Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
Department of Experimental Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
Cytokine. 2019 Jun;118:93-98. doi: 10.1016/j.cyto.2018.02.019. Epub 2018 Feb 24.
Increasing amount of evidence points to the importance of immunity in breast cancer. The prognostic value of cytokines and their effect on tumorigenesis remains inconsistent.
To investigate the prognostic significance of IL6 and IL8 and their association with ER and HER2 in estrogen-dependent (ER+) breast cancer.
The study included 79 premenopausal women with early and locally advanced ER+ breast cancer. All patients received adjuvant hormonal therapy: tamoxifen alone (56/79) or combination with LHRH agonist goserelin (23/79). IL6 and IL8 serum protein levels were measured by ELISA. Cox proportional hazards regression analysis was implemented for prognostic evaluation of the data categorized based on metastasis outcome.
IL6 associated with good (P = 0.001, HR = 0.05) and IL8 with poor disease outcome (P = 0.03, HR = 2.5) in the whole group of patients. Multivariate analyses highlighted IL6 as the independent prognostic factor (P = 0.001, HR = 0.0007). When patients were classified according to ER or HER2 status, IL6 did not have prognostic significance in ER and ER subgroups, while IL8 retained prognostic significance only in the ER subgroup (P = 0.04, HR = 2.8). IL6 was significant in both HER2- (P = 0.001, HR = 0.05) and HER2+ subgroups (P = 0.002, HR = 0.04), while IL8 retained its prognostic significance only in the HER2+ subgroup (P = 0.001, HR = 77.8).
This study contributes to the clarification of the prognostic performance of IL6 and IL8 by providing their first prognostic evaluation in the homogenized ER+ breast cancer patient group. IL6 was indicated as a marker of favorable, whereas IL8 was a marker of unfavorable disease outcome.
越来越多的证据表明免疫在乳腺癌中的重要性。细胞因子的预后价值及其对肿瘤发生的影响仍然不一致。
研究白细胞介素 6（IL6）和白细胞介素 8（IL8）在雌激素依赖性（ER+）乳腺癌中的预后意义及其与 ER 和 HER2 的关系。
本研究纳入了 79 例绝经前患有早期和局部晚期 ER+乳腺癌的女性患者。所有患者均接受辅助激素治疗：单独使用他莫昔芬（56/79）或联合使用 LHRH 激动剂戈舍瑞林（23/79）。采用 ELISA 法检测血清中 IL6 和 IL8 蛋白水平。基于转移结果对数据进行分类，采用 Cox 比例风险回归分析进行预后评估。
在整个患者组中，IL6 与良好的疾病结局相关（P=0.001，HR=0.05），IL8 与不良的疾病结局相关（P=0.03，HR=2.5）。多变量分析突出了 IL6 是独立的预后因素（P=0.001，HR=0.0007）。当根据 ER 或 HER2 状态对患者进行分类时，IL6 在 ER 和 ER 亚组中没有预后意义，而 IL8 仅在 ER 亚组中保留预后意义（P=0.04，HR=2.8）。IL6 在 HER2-（P=0.001，HR=0.05）和 HER2+亚组（P=0.002，HR=0.04）中均有意义，而 IL8 仅在 HER2+亚组中保留预后意义（P=0.001，HR=77.8）。
本研究通过对均质化的 ER+乳腺癌患者组进行首次预后评估，为 IL6 和 IL8 的预后表现提供了新的认识。IL6 被认为是疾病有利的标志物，而 IL8 是疾病不良结局的标志物。
